ReviewJournal of psychopharmacology (Oxford, England)2020
Medical cannabis in the UK: From principle to practice.
Review in Journal of psychopharmacology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Investigating medical cannabis for adolescents with Tourette syndrome: tread carefully.BJPsych open · 2026Article
- Development and validation of the Comprehensive Cannabis Motives Questionnaire (CCMQ).Journal of psychopharmacology (Oxford, England) · 2025Article
- Reducing medical cannabis use risk among Veterans: A descriptive study.Harm reduction journal · 2025Article
- Cannabis use by individuals with spinal cord injury in the UK: a call for improved patient education and physician awareness for pain and spasticity management.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2024Observational
- Illicit Cannabis Use to Self-Treat Chronic Health Conditions in the United Kingdom: Cross-Sectional Study.JMIR public health and surveillance · 2024Article
- The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products.Journal of cannabis research · 2024Article
- Review
- Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users.Frontiers in psychology · 2023Article
- Dysmenorrhoea: Can Medicinal Cannabis Bring New Hope for a Collective Group of Women Suffering in Pain, Globally?International journal of molecular sciences · 2022Review
- Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021-2022 survey.BMC primary care · 2022Article
- A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.Cannabis and cannabinoid research · 2022Article
- Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.Inflammopharmacology · 2022Review
- Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.Psychopharmacology · 2022Article
- To Treat or Not to Treat? Polish Physicians' Opinions about the Clinical Aspects of Cannabinoids-An Online Survey.Journal of clinical medicine · 2022Article
- Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
- Treating pain related to Ehlers-Danlos syndrome with medical cannabis.BMJ case reports · 2021Article
- Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.Journal of psychopharmacology (Oxford, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the UK, medical cannabis was approved in November 2018, leading many patients to believe that the medicine would now be available on the NHS. Yet, to date, there have been only 12 NHS prescriptions and less than 60 prescriptions in total. In marked contrast, a recent patient survey by the Centre for Medical Cannabis (Couch, 2020) found 1.4 m people are using illicit cannabis for medical problems.
aimsSuch a mismatch between demand and supply is rare in medicine. This article outlines some of the current controversies about medical cannabis that underpin this disparity, beginning by contrasting current medical evidence from research studies with patient-reported outcomes. OUTCOMES: Although definite scientific evidence is scarce for most conditions, there is significant patient demand for access to medical cannabis. This disparity poses a challenge for prescribers, and there are many concerns of physicians when deciding if, and how, to prescribe medical cannabis which still need to be addressed. Potential solutions are outlined as to how the medical profession and regulators could respond to the strong demand from patients and families for access to medical cannabis to treat chronic illnesses when there is often a limited scientific evidence base on whether and how to use it in many of these conditions.
conclusionsThere is a need to maximise both clinical research and patient benefit, in a safe, cautious and ethical manner, so that those patients for whom cannabis is shown to be effective can access it. We hope our discussion and outlines for future progress offer a contribution to this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.